PRISM BioLab Co., Ltd. (PRISM) and Receptor.AI Inc. declared a new partnership to find drugs. The collaboration will create a state-of-the-art platform based on AI and physics-based simulation.
The groups are seeking to target difficult targets within the cells including protein-protein interactions (PPIs) and complicated receptor systems. This is an integrated method that they wish to develop small-molecule orally ingestible drugs. The partnership is a combination of the PepMetics chemistry of PRISM and the AI-based navigation engine of Receptor.AI. The combination will present new possibilities of drug discovery.
The firms will use their technologies to generate hit, lead, and clinical candidate compounds. These are usually difficult to reach using conventional drug-discovery techniques.
AI-Powered Innovation in Drug Discovery
First, the cooperation will be centered on a certain receptor target, wherein Receptor.AI will proceed in molecular design with the help of high-quality AI algorithms. This will integrate the chemical space of PRISM with AI-based knowledge, which will enhance accuracy and efficiency in identifying potential drugs.
The two companies will collaborate with pharmaceutical companies to expand the use of their partner technologies. In addition to the purposes of the traditional research, the partnership aims to demonstrate the efficacy of combining AI with advanced chemistry.
Expanding Capabilities Through Strategic Collaboration
The firms will create clinical candidates and valuable expertise. Such knowledge will be used in future proposals to the potential partners. Dai Takehara, President and CEO of PRISM BioLab, was hopeful of the collaboration. He noted the advantage of PepMetics 2 Technology in the field of protein-protein interactions (PPIs).
Another point that he brought out was the potential of the PepMetics® Library. The library had the potential to be used on intracellular targets and difficult membrane proteins. Through the AI-based molecular design of Receptor.AI, the potential of the platform is likely to increase many times over. Such a combination would create new avenues to drug discovery.
Read :Â Is Model Governance Slowing AI in Financial Crime Fight?
Future Outlook: Smarter and Faster Drug Development
Founder and CEO of Receptor.AI Dr. Alan Nafiiev pointed out a shift towards old-fashioned screening techniques. He emphasized a more intelligent, navigation, discovery. The combination of Quorum Map and physics-informed modeling will increase decision-making and improve the choice of potential drug candidates.
The platform ensures selectivity, stability, and permeability, enabling the development of orally usable compounds. PRISM and Receptor.AI aim to transform drug discovery with a new approach. Their collaboration focuses on delivering innovative therapies faster and with greater scientific precision.
